Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Operating Margin: 2021-2025

Historic Operating Margin for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to -102.64%.

  • Rhythm Pharmaceuticals' Operating Margin rose 2934.00% to -102.64% in Q3 2025 from the same period last year, while for Sep 2025 it was -106.81%, marking a year-over-year increase of 12914.00%. This contributed to the annual value of -204.04% for FY2024, which is 3407.00% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Operating Margin stood at -102.64% for Q3 2025, which was down 9.91% from -93.39% recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Operating Margin's 5-year high stood at -93.39% during Q2 2025, with a 5-year trough of -98,280.00% in Q1 2021.
  • Moreover, its 3-year median value for Operating Margin was -143.73% (2025), whereas its average is -210.40%.
  • Its Operating Margin has fluctuated over the past 5 years, first spiked by 9,476,258bps in 2022, then slumped by 8,068bps in 2024.
  • Rhythm Pharmaceuticals' Operating Margin (Quarterly) stood at -2,806.22% in 2021, then soared by 232,723bps to -478.99% in 2022, then spiked by 30,871bps to -170.28% in 2023, then skyrocketed by 7,165bps to -98.63% in 2024, then surged by 2,934bps to -102.64% in 2025.
  • Its Operating Margin stands at -102.64% for Q3 2025, versus -93.39% for Q2 2025 and -143.73% for Q1 2025.